Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27. doi:10.1158/1055-9965. EPI-15-0578.
   PubMed Web of Science ®Google Scholar
• Noone AM, Howlader N, Krapcho M, et al. SEER cancer statistics review, 1975–2015; 2018, National Cancer Institute. Bethesda, MD. based on November 2017 SEER data submission, posted to the SEER web site, April 2018. Available from: https://seer.cancer.gov/csr/1975_2015/. Accessed July 14, 2021.
   Google Scholar
• Rustgi AK, El-Serag HB, Ingelfinger JR. Esophageal carcinoma. N Engl J Med. 2014;371:2499–2509. doi:10.1056/NEJMra1314530
   PubMed Web of Science ®Google Scholar
• Freedman ND, Abnet CC, Caporaso NE, et al. Impact of changing US cigarette smoking patterns on incident cancer: risks of 20 smoking-related cancers among the women and men of the NIHAARP cohort. Int J Epidemiol. 2016;45(3):846–856. doi:10.1093/ije/dyv175
   PubMed Web of Science ®Google Scholar
• Islami F, Fedirko V, Tramacere I, et al. Alcohol drinking and esophageal squamous cell carcinoma with focus on light-drinkers and never-smokers: a systematic review and meta-analysis. Int J Cancer. 2011;129(10):2473–2484. doi:10.1002/ijc.25885
   PubMed Web of Science ®Google Scholar
• Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body fatness and cancer—viewpoint of the IARC working group. N Engl J Med. 2016;375(8):794–798. doi:10.1056/NEJMsr1606602
   PubMed Web of Science ®Google Scholar
• Thrift AP, Shaheen NJ, Gammon MD, et al. Obesity and risk of esophageal adenocarcinoma and Barrett’s esophagus: a Mendelian randomization study. J Natl Cancer Inst. 2014;106(11):dju252. doi:10.1093/jnci/dju252
   PubMedGoogle Scholar
• Peleteiro B, Bastos A, Ferro A, et al. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci. 2014;59(8):1698–1709. doi:10.1007/s10620-014-3063-0
   PubMed Web of Science ®Google Scholar
• Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174. doi:10.1136/bmj.g3174
   PubMed Web of Science ®Google Scholar
• Doorakkers E, Lagergren J, Engstrand L, et al. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut. 2018;67(12):2092–2096. doi:10.1136/gutjnl-2017-315363
   PubMed Web of Science ®Google Scholar
• Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212–239. doi:10.1038/ajg.2016.563
   PubMed Web of Science ®Google Scholar
• Liyanage SS, Rahman B, Ridda I, et al. The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis. PLoS One. 2013;8(7):e69238. doi:10.1371/journal.pone.0069238
   PubMed Web of Science ®Google Scholar
• Rajendra S, Xuan W, Merrett N, et al. Survival rates for patients with Barrett high-grade dysplasia and esophageal adenocarcinoma with or without human papillomavirus infection. JAMA Netw Open. 2018;1(4):e181054. doi:10.1001/jamanetworkopen.2018.1054
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–209. doi:10.1038/nature13480
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169. doi:10.1038/nature20805
   PubMed Web of Science ®Google Scholar
• Janmaat VT, Steyerberg EW, van der Gaast A, et al. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev. 2017;11:Cd004063. doi:10.1002/14651858.CD004063.pub4
   PubMedGoogle Scholar
• Al-Batran S, Hartmann J, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435–1442. doi:10.1200/JCO.2007.13.9378
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46. doi:10.1056/NEJMoa073149
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van CE, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:1302. doi:10.1016/S0140-6736(10)61121-X
   PubMed Web of Science ®Google Scholar
• Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014;32:3520–3526. doi:10.1200/jco.2013.54.1011
   PubMed Web of Science ®Google Scholar
• Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19:1450–1457. doi:10.1093/annonc/mdn166
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek T, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–39. doi:10.1016/s0140-6736(13)61719-5
   PubMed Web of Science ®Google Scholar
• Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–1235. doi:10.1016/s1470-2045(14)70420-6
   PubMed Web of Science ®Google Scholar
• Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15:78–86. doi:10.1016/s1470-2045(13)70549-7
   PubMed Web of Science ®Google Scholar
• Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47:2306–2314. doi:10.1016/j.ejca.2011.06.002
   PubMed Web of Science ®Google Scholar
• Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31:4438–4444. doi:10.1200/jco.2012.48.5805
   PubMed Web of Science ®Google Scholar
• Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437–1448. doi:10.1016/S1470-2045(18)30739-3
   PubMed Web of Science ®Google Scholar
• Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35:446–464. doi:10.1200/jco.2016.69.4836
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476–484. doi:10.1007/s10120-014-0402-y
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39–51. doi:10.1056/NEJMra043186
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. doi:10.1016/s0140-6736(10)61121-x
   PubMed Web of Science ®Google Scholar
• Bang YJ. A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study. J Clin Oncol. 2013;31:11. doi:10.1200/jco.2013.31.4_suppl.11
   PubMedGoogle Scholar
• Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18:640–653. doi:10.1016/S1470-2045(17)30111-0
   PubMed Web of Science ®Google Scholar
• Tabernero J, Ho PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19:1372–1384. doi:10.1016/S1470-2045(18)30481-9
   PubMed Web of Science ®Google Scholar
• Hecht JR, Bang YJ, Qin SK, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC–a randomized phase III trial. J Clin Oncol. 2016;34:443–451. doi:10.1200/JCO.2015.62.6598
   PubMed Web of Science ®Google Scholar
• Al-Shamsi HO, Fahmawi Y, Dahbour I, et al. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. J Gastrointest Oncol. 2016;7:499–505. doi:10.21037/jgo.2016.06.16
   PubMedGoogle Scholar
• Palle J, Tougeron D, Pozet A, et al. Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. J Clin Oncol. 2017;35:94. doi:10.1200/JCO.2017.35.4_suppl.94
   Web of Science ®Google Scholar
• Li Q, Jiang H, Li H, et al. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. Oncotarget. 2016;7:50656–50665. doi:10.18632/oncotarget.10456
   PubMed Web of Science ®Google Scholar
• Makiyama A, Sagara K, Kawada J, et al. A randomized phase II study of weekly paclitaxel _ trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT). J Clin Oncol. 2018;36:4011. doi:10.1200/JCO.2018.36.15_suppl.4011
   Web of Science ®Google Scholar
• Saeki H, Oki E, Kashiwada T, et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Eur J Cancer. 2018;105:41–49. doi:10.1016/j.ejca.2018.09.024
   PubMed Web of Science ®Google Scholar
• Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097–5108. doi:10.1158/1078-0432.CCR-15-2822
   PubMed Web of Science ®Google Scholar
• Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–2430. doi:10.1056/NEJMoa2004413
   PubMed Web of Science ®Google Scholar
• Yu S, Park J, Kwon W, et al. Trastuzumab deruxtecan (T-DXd) sensitivity in various levels of HER2 expressing gastric cancer cells. Presented at: AACR Annual Meeting 2021; April 10–15, 2021; Virtual. Abstract 945.
   Google Scholar
• Seo S, Park S, Ryu M, et al. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers. Oncotarget. 2017;8(20):33844–33854. doi:10.18632/oncotarget.12953
   PubMedGoogle Scholar
• Han N, Kim MA, Lee HS, Kim WH. Evaluation of fibroblast growth factor receptor 2 expression, heterogeneity and clinical significance in gastric cancer. Pathobiology. 2015;82(6):269–279. doi:10.1159/000441149
   PubMed Web of Science ®Google Scholar
• Ahn S, Lee J, Hong M, et al. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Mod Pathol. 2016;29(9):1095–1103. doi:10.1038/modpathol.2016.96
   PubMed Web of Science ®Google Scholar
• Nagatsuma AK, Aizawa M, Kuwata T, et al. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer. 2015;18(2):227–238. doi:10.1007/s10120-014-0360-4
   PubMed Web of Science ®Google Scholar
• Tokunaga R, Imamura Y, Nakamura K, et al. Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma. Oncotarget. 2016;7(15):19748. doi:10.18632/oncotarget.7782
   PubMedGoogle Scholar
• Wainberg ZA, Enzinger PC, Kang YK, et al. Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT). J Clin Oncol. 2021;39(3_suppl):160. doi:10.1200/JCO.2021.39.3_suppl.160
   Web of Science ®Google Scholar
• Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006;12:5018–5022. doi:10.1158/1078-0432.CCR-06-1520
   PubMed Web of Science ®Google Scholar
• Tanaka T, Ishiguro H, Kuwabara Y, et al. Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res. 2010;29:83. doi:10.1186/1756-9966-29-83
   PubMed Web of Science ®Google Scholar
• Omoto I, Matsumoto M, Okumura H, et al. Expression of vascular endothelial growth factor-C and vascular endothelial growth factor receptor-3 in esophageal squamous cell carcinoma. Oncol Lett. 2014;7:1027–1032. doi:10.3892/ol.2014.1823
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328–335. doi:10.1016/j.bbrc.2005.05.132
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, de Haas S, Kang Y-K, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;30:2119–2127. doi:10.1200/jco.2011.39.9824
   PubMed Web of Science ®Google Scholar
• Lorenzen S, Thuss-Patience PC, Pauligk C, et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel- results from the phase II RAMIRIS Study of the AIO. ASCO Abstr. 2020;38(15):4514. doi:10.1200/JCO.2020.38.15_suppl.4514
   Google Scholar
• Klempner SJ, Maron SB, Chase L, et al. Initial report of second-line FOLFIRI in combination with ramucirumab in advanced gastroesophageal adenocarcinomas: a multi-institutional retrospective analysis. Oncologist. 2019;24(4):475–482. doi:10.1634/theoncologist.2018-0602. PMID: 30470690; PMCID: PMC6459251.
   PubMed Web of Science ®Google Scholar
• Kelly RJ. Immunotherapy for esophageal and gastric cancer. Am Soc Clin Oncol Educ Book. 2017;37:292–300. doi:10.1200/EDBK_175231
   PubMedGoogle Scholar
• Ahn E, Araki K, Hashimoto M, et al. Role of PD-1 during effector CD8 T cell differentiation. Proc Natl Acad Sci USA. 2018;115:4749–4754. doi:10.1073/pnas.1718217115
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013. doi:10.1001/jamaoncol.2018.0013
   PubMed Web of Science ®Google Scholar
• Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–2471. doi:10.1016/S0140-6736(17)31827-5
   PubMed Web of Science ®Google Scholar
• Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN gastric 300. Ann Oncol. 2018;29:2052–2060. doi:10.1093/annonc/mdy264
   PubMed Web of Science ®Google Scholar
• Kojima T, Muro K, Francois E, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: the phase 3 KEYNOTE-181 study. 2019 Gastrointestinal Cancers Symposium; Presented January 17, 2019; Abstract 2.
   Google Scholar
• Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506–1517. doi:10.1016/S1470-2045(19)30626-6
   PubMed Web of Science ®Google Scholar
• Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21(6):832–842. doi:10.1016/S1470-2045(20)30110-8
   PubMed Web of Science ®Google Scholar
• BeiGene, Ltd. BeiGene announces positive topline results for global phase 3 trial of tislelizumab in esophageal squamous cell carcinoma; 2021. Available from: http://bit.ly/39qV6Hn. Accessed January 28, 2021.
   Google Scholar
• Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–4148. doi:10.1200/JCO.20.01888. PMID: 33026938.
   PubMed Web of Science ®Google Scholar
• Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–133. doi:10.1016/S0140-6736(18)31257-1
   PubMed Web of Science ®Google Scholar
• Nakajima TE, Kadowaki S, Minashi K, et al. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. Clin Cancer Res. 2021;27:1029–1036. doi:10.1158/1078-0432.CCR-20-3559
   PubMed Web of Science ®Google Scholar
• Moehler M, Dvorkin M, Boku N, et al. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN gastric 100. J Clin Oncol. 2020;39:JCO–20.
   Web of Science ®Google Scholar
• Shitara K, Van Cutsem E, Bang Y, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571–1580. doi:10.1001/jamaoncol.2020.3370
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40. doi:10.1016/S0140-6736(21)00797-2
   PubMed Web of Science ®Google Scholar
• Bristol Myers Squibb. US food and drug administration approves opdivo (nivolumab) in combination with chemotherapy for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma; 2021. Available from: https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Approves-Opdivo-nivolumab-in-Combination-with-Chemotherapy-for-Patients-with-Advanced-or-Metastatic-Gastric-Cancer-Gastroesophageal-Junction-Cancer-and-Esophageal-Adenocarcinoma/default.aspx. Accessed April 16, 2021.
   Google Scholar
• Janjigian YY, Kawazoe A, Yanez PE, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: initial findings of the global phase 3 KEYNOTE-811 study. J Clin Oncol. 2021;39(15_suppl):4013. doi:10.1200/JCO.2021.39.15_suppl.4013
   Web of Science ®Google Scholar
• NCCN. NCCN development and update of guidelines; 2021. Available from: https://www.nccn.org/guidelines/guidelines-process/development-and-update-of-guidelines. Accessed June 24, 2021.
   Google Scholar
• Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29:482–491. doi:10.1038/onc.2009.356
   PubMed Web of Science ®Google Scholar
• Terenzi A, Pirker C, Keppler BK, Berger W. Anticancer metal drugs and immunogenic cell death. J Inorg Biochem. 2016;165:71–79. doi:10.1016/j.jinorgbio.2016.06.021
   PubMed Web of Science ®Google Scholar
• Bezu L, Gomes-da-silva LC, Dewitte H, et al. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol. 2015;6:187.
   PubMed Web of Science ®Google Scholar
• Martins I, Kepp O, Schlemmer F, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene. 2011;30(10):1147–1158. doi:10.1038/onc.2010.500
   PubMed Web of Science ®Google Scholar
• Aranda F, Bloy N, Pesquet J, et al. Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. Oncogene. 2015;34(23):3053–3062. doi:10.1038/onc.2014.234
   PubMed Web of Science ®Google Scholar
• Park SJ, Ye W, Xiao R, et al. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. Oral Oncol. 2019;95:127–135. doi:10.1016/j.oraloncology.2019.06.016
   PubMed Web of Science ®Google Scholar
• Boku N, Ryu MH, Oh DY, et al. Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study. Ann Oncol. 2020;31:1142–1215. doi:10.1016/j.annonc.2020.08.2297
   Web of Science ®Google Scholar
• Lei M, Siemers NO, Pandya D, et al. Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab±ipilimumab in gastric cancer/gastroesophageal junction cancer. Clin Cancer Res. 2021;27(14):3926–3935.
   Web of Science ®Google Scholar
• Kato K, Sun JM, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study. Ann Oncol. 2020;31:S1192–S1193. doi:10.1016/j.annonc.2020.08.2298
   Web of Science ®Google Scholar
• FDA. FDA approves pembrolizumab for esophageal or GEJ carcinoma; 2021. Available from: https://bit.ly/3191ONi. Accessed March 22, 2021.
   Google Scholar
• FDA. Meeting of the oncologic drugs advisory committee meeting announcement; 2021. Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-27-29-2021-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04272021-04292021. Accessed April 29, 2021.
   Google Scholar
• Xu RH, Luo H, Lu J, et al. ESCORT-1st: a randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy vs chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC). J Clin Oncol. 2021;39(suppl 15):4000. doi:10.1200/JCO.2021.39.15_suppl.4000
   PubMedGoogle Scholar
• Chau I, Doki Y, Ajani JA, et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the CheckMate 648 study. J Clin Oncol. 2021;39(18_suppl):LBA4001–LBA4001. doi:10.1200/JCO.2021.39.15_suppl.LBA4001
   Web of Science ®Google Scholar
• Liu L, Yang Y, Burns R, et al. Margetuximab mediates greater Fc-dependent anti-tumor activities than trastuzumab or pertuzumab in vitro. Cancer Res. 2019;79(Suppl.13):Abstract 1538.
   Google Scholar
• Nordstrom JL, Gorlatov S, Zhang W, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res. 2011;13(6):R123. doi:10.1186/bcr3069
   PubMed Web of Science ®Google Scholar
• Nordstrom JL, Muth J, Erskine CL, et al. High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb). J Clin Oncol. 2019;37(Suppl.15):Abstract 1030. doi:10.1200/JCO.2019.37.15_suppl.1030
   Web of Science ®Google Scholar
• Catenacci DV, Kang YK, Park H, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal phase 1b-2 trial. Lancet Oncol. 2020;2045:1–11.
   Google Scholar
• Catenacci DV, Rosales M, Chung HC, et al. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncol. 2021;17:1155–1164. doi:10.2217/fon-2020-1007
   PubMed Web of Science ®Google Scholar
• Rha SY, Lee C-K, Kim HS, et al. A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2-positive advanced gastric and gastroesophageal junction cancer (PANTHERA Trial): molecular profiling and clinical update. J Clin Oncol. 2021;39:218. doi:10.1200/JCO.2021.39.3_suppl.218
   Web of Science ®Google Scholar
• Hao D, He S, Harada K, et al. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut. 2020;gutjnl-2020-322707. doi:10.1136/gutjnl-2020-322707
   Web of Science ®Google Scholar
• Sahin U, Türeci Ö, Manikhas G, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18. 2 positive gastric and gastro-oesophageal adenocarcinomas. Ann Oncol. 2021;32:609–619. doi:10.1016/j.annonc.2021.02.005
   PubMed Web of Science ®Google Scholar
• Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8þ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14:e0212513. doi:10.1371/journal.pone.0212513
   PubMed Web of Science ®Google Scholar
• Lwin Z, Gomez-Roca C, Saada-Bouzid E, et al. Phase II study of Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumors. Ann Oncol. 2020;31(suppl_4):S1142–S1215. doi:10.1016/j.annonc.2020.08.2271
   Google Scholar
• Kawazoe A, Fukuoka S, Nakamura Y, et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1057–1065. doi:10.1016/S1470-2045(20)30271-0
   PubMed Web of Science ®Google Scholar
• Catenacci DV, Kang YK, Park H, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial. Lancet Oncol. 2020;21(8):1066–1076. doi:10.1016/S1470-2045(20)30326-0
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44:989–1004. doi:10.1016/j.immuni.2016.05.001
   PubMed Web of Science ®Google Scholar
• Bristol Myers Squibb. Bristol Myers Squibb announces RELATIVITY-047, a trial evaluating anti-LAG-3 antibody relatlimab and opdivo (nivolumab) in patients with previously untreated metastatic or unresectable melanoma, meets primary endpoint of progression-free survival. News release; 2021. Available from: https://bit.ly/3ffwCnI. Accessed March 25, 2021.
   Google Scholar
• Yang L, Wang Y, Wang H. Use of immunotherapy in the treatment of gastric cancer. Oncol Lett. 2019;18:5681–5690.
   PubMedGoogle Scholar
• Beîbnowska D, Grywalska E, Nied_zwiedzka-Rystwej P, et al. CAR-T cell therapy-an overview of targets in gastric cancer. J Clin Med. 2020;9:1894. doi:10.3390/jcm9061894
   PubMed Web of Science ®Google Scholar
• Song Y, Tong C, Wang Y, et al. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. Protein Cell. 2018;9:867–878. doi:10.1007/s13238-017-0384-8
   PubMed Web of Science ®Google Scholar
• Maher J, Wilkie S. CAR mechanics: driving T cells into the MUC of cancer. Cancer Res. 2009;69:4559–4562. doi:10.1158/0008-5472.CAN-09-0564
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Single-arm, two phase, multicenter trial to evaluating the efficacy and safety of the CAR-T for stomach cancer; 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT02725125. Accessed March 15, 2020.
   Google Scholar
• Knödler M, Körfer J, Kunzmann V, et al. Randomised phase II trial to investigate catumaxomab (anti-EpCAM_anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. Br J Cancer. 2018;119:296–302. doi:10.1038/s41416-018-0150-6
   PubMed Web of Science ®Google Scholar
• Dottermusch M, Krüger S, Behrens HM, Halske C, Röcken C. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study. Virchows Arch. 2019;475:563–571. doi:10.1007/s00428-019-02624-7
   PubMed Web of Science ®Google Scholar
• Singh P, Toom S, Huang Y. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol. 2017;10:105. doi:10.1186/s13045-017-0473-4
   PubMed Web of Science ®Google Scholar
• Jiang H, Shi Z, Wang P, et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J Natl Cancer Inst. 2019;111:409–418. doi:10.1093/jnci/djy134
   PubMedGoogle Scholar
• PR Newswire. CARsgen therapeutics receives IND clearance from the US FDA for CT041 CLDN18.2-CAR-T cells; 2021. Available from: https://www.prnewswire.com/news-releases/carsgen-therapeutics-receives-ind-clearancefrom-the-us-fda-for-ct041-cldn18-2-car-t-cells-301060555.html. Accessed June 6, 2020.
   Google Scholar
• clinicaltrials.gov. Open-label, multicenter, phase 1b clinical trial to evaluate the safety and efficacy of autologous claudin 18.2 chimeric antigen receptor T-cell therapy in patients with advanced gastric or pancreatic adenocarcinoma; 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04404595. Accessed June 6, 2020.
   Google Scholar
• Zhan X, Wang B, Li Z, et al. Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma. J Clin Oncol. 2019;37:2509. doi:10.1200/JCO.2019.37.15_suppl.2509
   Google Scholar
• Kankeu Fonkoua LA, Chakrabarti S, Sonbol MB, et al. Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. Int J Cancer. 2021;149:1–9. doi:10.1002/ijc.33559.
   Web of Science ®Google Scholar
• Yoon HH, Fuchs CS, Özgüroğlu M, et al. O-12 KEYNOTE-061: response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma. Ann Oncol. 2020;31:236. doi:10.1016/j.annonc.2020.04.065
   PubMed Web of Science ®Google Scholar
• Sasaki A, Kawazoe A, Eto T, et al. Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open. 2020;4(Suppl 2):e000775. doi:10.1136/esmoopen-2020-000775
   PubMed Web of Science ®Google Scholar
• Kawazoe A, Ando T, Hosaka H, et al. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(3):209–217. doi:10.1016/S2468-1253(20)30396-4
   PubMed Web of Science ®Google Scholar
• Zhu M, Sonbol MB, Yoon HH. Trifluridine/tipiracil plus ramucirumab in gastric cancer. Lancet Gastroenterol Hepatol. 2021;6:154–155. doi:10.1016/S2468-1253(21)00013-3
   PubMed Web of Science ®Google Scholar
• Chin K, Kato K, Cho BC, et al. Three-year follow-up of ATTRACTION-3: a phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy. J Clin Oncol. 2021;39:204. doi:10.1200/JCO.2021.39.3_suppl.204
   Web of Science ®Google Scholar
• Cho J, Kang MS, Kim KM. Epstein-barr virus-associated gastric carcinoma and specific features of the accompanying immune response. J Gastric Cancer. 2016;16:1–7. doi:10.5230/jgc.2016.16.1.1
   PubMed Web of Science ®Google Scholar
• Van Beek J, Zur Hausen A, Klein Kranenbarg E, et al. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol. 2004;22:664–670. doi:10.1200/JCO.2004.08.061
   PubMed Web of Science ®Google Scholar
• Camargo MC, Murphy G, Koriyama C, et al. Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. Br J Cancer. 2011;105:38–43. doi:10.1038/bjc.2011.215
   PubMed Web of Science ®Google Scholar
• Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24:1449–1458. doi:10.1038/s41591-018-0101-z
   PubMed Web of Science ®Google Scholar
• Rha SY, Lee JB, Kim HS, et al. Open label, single-arm, multi-center phase Ib/II study to evaluate the safety and efficacy of nivolumab in combination with paclitaxel in Epstein-Barr virus (EBV)-related, or microsatellite instability-high (MSI-H), or programmed cell death ligand 1 (PD-L1) positive advanced gastric cancer (AGC). Presented at: AACR Annual Meeting 2021; April 10–15, 2021; Virtual. Abstract CT159.
   Google Scholar
• Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:490–499. doi:10.1016/S1470-2045(13)70102-5
   PubMed Web of Science ®Google Scholar
• Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:481–489. doi:10.1016/S1470-2045(13)70096-2
   PubMed Web of Science ®Google Scholar
• Shah MA, Bang YJ, Lordick F, et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial. JAMA Oncol. 2017;3:620–627. doi:10.1001/jamaoncol.2016.5580
   PubMed Web of Science ®Google Scholar
• Catenacci DVT, Tebbutt NC, Davidenko I, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1467–1482. doi:10.1016/S1470-2045(17)30566-1
   PubMed Web of Science ®Google Scholar